Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Prof. Dr Kouzarides and his co-workers from Cancer Research Gurdon Institute, University of Cambridge, UK report in the prestigious journal Molecular Cell (2014) that “The Breast Cancer Oncogene EMSY Represses Transcription of Antimetastatic microRNA miR-31”
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Mechanistic insights into mammary tumorigenesis: EMSY increases the expression of polycomb group (PcG) protein BMI1 and suppresses the expression of INK4a/ARF via down regulation of its target gene.
Significance: This study suggests, for the first time, that EMSY, by suppressing the expression of its target gene, it may increase the expression of tumor suppressor BMI1; and suppress the expression of INK4a/ARF. Thus, pharmacological formulations encompassing “EMSY inhibitors“ can be used to inhibit the progression of human tumors.
Citation: Boominathan, Mechanistic insights into mammary tumorigenesis: The mammary cancer oncogene EMSY increases the expression of polycomb group (PcG) protein BMI1 and suppresses the expression of INK4a/ARF via down regulation of its target gene, 5/March/2015, 22.10, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Web: http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
Undisclosed information: How EMSY increases the expression of tumor suppressor BMI1 and suppresses the expression of INK4a/ARF
Amount: $ 500*
* Research cooperation
